Cognizant Technology Solutions (CTSH)

Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is mixed-to-cautious — consensus is a manageable bar (revenue growth of ~4.7% YoY to ~$5.49B) but the stock has already de-rated sharply since last earnings, and the single biggest swing factor is whether large deal ramp-ups and the Astreya inorganic contribution are enough to offset continued softness in discretionary spend.

Heading into the Q2 2026 print, the bar for CTSH is not particularly high: consensus revenue of ~$5.49B sits near the midpoint of the $5.45–$5.52B guidance range issued on April 29, and adjusted EPS consensus of ~$1.38 is modestly above the implied quarterly run-rate of the raised full-year guide of $5.63–$5.77. Management's tone shifted more cautious at Q1 earnings — explicitly flagging heightened macro uncertainty and softening discretionary spend — and the CFO reiterated at the June 10 Jefferies conference that no acceleration in discretionary spend had been observed since then, characterizing recovery as likely still multiple quarters away. Estimate revisions have been essentially flat-to-slightly-down since the Q1 print (Q2 revenue consensus drifted from ~$5.50B to ~$5.49B), suggesting the street has largely absorbed the cautious tone without a meaningful reset. The stock has been severely punished — down ~29% from the April 29 earnings close of $54.70 to a recent low near $38.73 on June 30, before recovering to ~$50.33 as of July 28 — meaning the multiple has already compressed dramatically (NTM P/E ~8x vs. ~15x six months ago), and the stock is no longer pricing in a beat. The key wildcard is

large deal conversion and Astreya revenue contribution: management guided for ~150bps of inorganic contribution in Q2 and flagged that large deal transitions from Q4 2025 and Q1 2026 were expected to unlock in Q2–Q3; if those ramps are on track, the print could surprise to the upside on revenue even in a soft discretionary environment. Conversely, any signal that deal slippage (as seen at IBM in Q2) has also affected CTSH's pipeline would be a meaningful negative.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar — revenue and EPS estimates have barely moved since the Q1 print, sitting near guidance midpoints.

Revenue is the bigger swing factor: whether large deal ramps and Astreya (~150bps inorganic) deliver on schedule will determine whether CTSH prints at the top or bottom of its own guidance range. Adjusted EPS has more cushion given the raised full-year guide and Project Leap savings.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data; CTSH Q1 2026 Earnings Release (April 29, 2026). Revenue consensus: $5.487B. Adj. EPS consensus: $1.378. Adj. Operating Income consensus: $869M. All consensus figures as of July 29, 2026.

Table 2 — Beat / Miss History (Last 8 Quarters, Top 2 KPIs)

Pattern: CTSH has beaten consensus on both Revenue and Adjusted EPS in each of the last 8 quarters, with EPS beats consistently larger (averaging ~5–7%) than revenue beats (averaging ~1%). This persistent beat pattern suggests consensus is typically set conservatively, but the Q1 2026 revenue result was essentially in-line, signaling the beat cushion on the top line may be narrowing as macro headwinds intensify.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not been formally revised since the Q1 2026 earnings call (April 29), but management's tone has remained cautious — the CFO confirmed at the June 10 Jefferies conference that the demand environment had not materially improved, and discretionary recovery is likely still multiple quarters away. The one post-earnings action was a meaningful expansion of the share repurchase program (May 18), framed as a confidence signal in the AI-led growth thesis.

Sources: CTSH Q1 2026 Earnings Release and Transcript (April 29, 2026); Cognizant Share Repurchase Press Release (May 18, 2026); Jefferies Conference commentary (June 10, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 revenue consensus drifted only ~$13M lower (from $5.500B to $5.487B) and FY 2026 revenue drifted ~$4M lower, suggesting the street largely accepted management's cautious framing without a meaningful downward reset. The gap between consensus and the guidance midpoint is minimal on revenue, while EPS consensus sits comfortably within the raised full-year range, implying the bar is achievable but not easy.

Commentary: The near-zero estimate drift since the Q1 print is notable — it suggests the street has neither capitulated further on the macro headwind narrative nor built in meaningful upside from large deal ramps or Astreya. FY 2026 revenue consensus sitting ~$86M below the guidance midpoint reflects residual skepticism about H2 discretionary recovery, which management itself acknowledged is likely still multiple quarters away. Any Q2 revenue print at or above the guidance midpoint, combined with maintained full-year guidance, would likely be read as a modest positive.

Source: Visible Alpha Consensus and Actuals Data (revision history table, weekly frequency, May 1 – July 29, 2026).

5. Stock Performance

Key Takeaway: The stock's ~8% decline since the April 29 earnings close (to ~$50.33 as of July 28) massively understates the intra-period pain — CTSH fell as low as $38.73 on June 30, a ~29% drawdown, driven almost entirely by multiple compression (NTM EV/EBITDA collapsed from ~9.6x to ~4.2x at the trough) rather than estimate cuts. The sharp recovery in late July (+30% off the lows) appears sentiment/multiple-driven, not earnings-driven, leaving the stock still deeply discounted vs. history.

CTSH vs. IGV (iShares Expanded Tech-Software ETF) vs. S&P 500 — Indexed to 100 at April 29, 2026 (Last Earnings Date)

Performance Summary (Apr 29 → Jul 28): CTSH: -8.1% | IGV: +8.6% | SPY: +4.1%. CTSH dramatically underperformed both the software sector ETF and the broader market over the period, with the divergence most acute in June when ACN's guidance cut and broader IT services sector de-rating drove CTSH to its lows. The late-July recovery has been sharp but CTSH still lags IGV by ~17 percentage points since earnings.

Valuation Context: NTM EV/EBITDA compressed from ~9.6x (6 months ago) to a trough of ~4.2x and currently sits at ~5.1x — a ~47% multiple contraction over 6 months. NTM P/E is ~8x vs. ~15x six months ago. The stock is trading at a historically extreme discount, suggesting the market is pricing in sustained structural headwinds rather than a cyclical pause.

Sources: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (Implied platform, snapshot July 28, 2026).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the dramatic share repurchase expansion (May 18) — management's clearest signal of conviction in the AI-led thesis and a view that the stock is deeply undervalued. The Astreya acquisition close and the June 5 AI Forum product launches are the key operational catalysts to watch for in the Q2 print.

• May 18, 2026 — Share Repurchase Target Raised to $2B (+$1B): Board approved a $2B increase to the existing repurchase authorization (total remaining: ~$3.45B). Full-year 2026 buyback target raised from $1B to $2B, with the incremental $1B expected to be completed in Q2 2026. Funded via $1B draw on revolving credit facility. CEO Ravi Kumar framed this as "strong conviction in the long-term opportunity AI creates" and a view that "our current share price significantly undervalues those prospects." CFO noted at Jefferies (June 10) that this is a pull-forward of future years' repurchase capacity, not a permanent shift in capital allocation.
• Implication: Expect Q2 share count to be meaningfully lower, providing EPS tailwind. Watch for confirmation that the $1B incremental buyback was completed in Q2.
• Apr 29, 2026 — Astreya Acquisition Announced (Expected Close Q2 2026): Cognizant announced the acquisition of Astreya, a specialist in AI infrastructure, data center managed services, and enterprise networks with relationships across six of the largest hyperscalers. As of the June 10 Jefferies conference, the deal had not yet closed, with the CFO noting ~1 month of Astreya revenue had been budgeted into Q2 guidance.
• Implication: Astreya contributes ~150bps of the inorganic revenue growth embedded in Q2 guidance. Confirmation of close timing and initial revenue contribution will be key.
• Apr 29, 2026 — Project Leap Restructuring Announced: Cognizant launched Project Leap, a restructuring program targeting meaningful cost savings in 2026 (larger full-year benefit in 2027), enabling the raise to FY 2026 adjusted operating margin guidance (to 16.0%–16.2%) and EPS guidance. Program focuses on workforce pyramid reshaping, AI capability investment, and workforce reskilling.
• Implication: Watch for Q2 restructuring charges and progress on savings realization. Margin delivery will be a key positive if revenue is soft.
• Jun 5, 2026 — AI Forum: Multiple Product & Partnership Milestones: Cognizant showcased: (1) Cognizant AI Factory (launched March 2026 with Dell/NVIDIA, multi-tenant enterprise AI infrastructure with Fractional GPU technology); (2) TriZetto Unify made headless (May 29, 2026) enabling AI agent access to healthcare platform APIs; (3) Context engineering deployed live across global sales force via Work Fabric partnership, targeting ~$1B in pipeline by year-end; (4) Cognizant Skillspring AI-native learning platform (launched April 2026); (5) Sovereign Physical AI Platform-as-a-Service formally launched; (6) Cognizant Secure AI Services launched (May 7) with expanded CrowdStrike alliance (June 2). Key clients including LPL Financial, Elevance Health, Citizens Bank, US Bank, Lineage Logistics, Sysco Foods, and TD Bank publicly validated early AI wins.
• Implication: Positive for AI narrative and pipeline credibility; watch for any quantification of AI Forum-related bookings or pipeline in Q2 commentary.
• Jun 10, 2026 — Jefferies Conference (CFO Commentary): CFO confirmed demand environment had not materially changed since Q1 earnings — no acceleration in discretionary spend observed. BFSI leads AI investment; health sciences follows; manufacturing most impacted by geopolitical uncertainty; CMT remains weakest vertical. Europe showing positive momentum. CFO characterized discretionary recovery as likely still multiple quarters away. ACV growth over a couple of consecutive quarters identified as the clearest external signal of recovery.
• Implication: Negative read-through for Q2 discretionary revenue; reinforces the cautious guidance tone. Any improvement in ACV or discretionary commentary on the Q2 call would be a positive surprise.
• Jun 18, 2026 — Accenture Q3 FY26 Earnings (Peer Read-Through): ACN cut full-year revenue guidance to 3–4% local currency growth (from prior range), citing discretionary spend softness in the last few weeks of the quarter (May 2026) and longer decision-making in EMEA. ACN stock fell ~18% to a decade low.
• Implication: Significant negative read-through for CTSH Q2 — the ACN-flagged discretionary softness in May directly overlaps with CTSH's Q2 period. Likely contributed to CTSH's sharp decline to its June 30 lows.
• Jul 10, 2026 — Shareholder Derivative Suit Settlement (Preliminary Approval): Cognizant received preliminary court approval for settlement of a long-running stockholder derivative action. Settlement notice and agreement filed as 8-K exhibits.
• Implication: Removes a legal overhang; modest positive for sentiment but not a material financial event.
• Jul 14, 2026 — IBM Pre-Announced Q2 Miss (Peer Read-Through): IBM pre-announced Q2 revenue of $17.2B vs. $17.9B consensus, with CEO citing clients shifting budgets to supply-constrained hardware (servers, memory) ahead of expected price increases. IBM stock fell 25% — worst single-day decline in company history.
• Implication: Mixed read-through for CTSH. IBM's consulting segment was flat (not down), and consulting signings grew 6%. The CapEx-driven budget shift is more specific to IBM's mainframe/software stack than to CTSH's services model. However, the broader signal of client budget re-prioritization and large deal slippage is a risk factor for CTSH's own bookings.
• Jun 8, 2026 — Wedbush Upgrades CTSH to Outperform (from Neutral): Only analyst rating change in the period since Q1 earnings.
• Implication: Modest positive sentiment signal; suggests at least one firm views the post-earnings selloff as overdone.

7. Insider Transaction Activity

Key Takeaway: The most notable signal is a discretionary open-market purchase by Director Stephen Rohleder on June 10 — a rare buy at a time when the stock was near multi-year lows, suggesting at least one board member views the selloff as overdone. The two small sales by the SVP/Controller are 10b5-1 plan-driven and carry no informational content.

Source: SEC Form 4 Filings Database (Insider Transaction Data). Filing date window: April 29 – July 29, 2026.

8. Peer Commentaries & Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary is net cautious for CTSH's Q2 print — ACN's explicit call-out of discretionary spend softness in May (directly overlapping CTSH's Q2) and IBM's large deal slippage are the most relevant negative signals. However, both peers confirm AI-related demand is accelerating and consulting signings are growing, which is a positive read-through for CTSH's large deal pipeline and AI builder positioning.

Methodology Note: Only commentary that speaks to the forward/current reporting period or post-earnings events is included below. Retrospective commentary about each peer's own reported quarter results has been excluded. All commentary is from the last 60 days (approximately May 29 – July 29, 2026).

8A. Accenture (ACN) — Q3 FY2026 Earnings Call (June 18, 2026)

ACN's fiscal Q3 ended May 31, 2026, meaning its forward-looking commentary and its description of conditions in the "last few weeks of the quarter" (May 2026) directly overlaps with CTSH's Q2 2026 (April–June 2026). ACN's Q4 FY26 guidance (June–August 2026) covers the end of CTSH's Q2 and the start of CTSH's Q3.

Discretionary Spend — 🔴 Negative Read-Through for CTSH Q2

ACN CEO Julie Sweet stated that in the "last few weeks of the quarter" (i.e., May 2026), Accenture saw an "indirect impact globally in products and to a lesser degree in resources, mostly in discretionary spend." She added: "Because the indirect impact really started in the last few weeks and mostly in discretionary spend. We do think that there will be more impact in Q4, which is why we're saying that more of the range is in play in these areas." CFO Angie Park confirmed: "the impact that we saw was really at the latter part or the last few weeks of the quarter. And so we expect that to continue for the full of Q4."

CTSH Relevance: This is the single most important peer read-through for CTSH's Q2 print. ACN's explicit observation of discretionary spend softness in May 2026 — the middle of CTSH's Q2 — directly validates CTSH management's own cautious Q2 guidance tone. The expectation that this softness would continue into ACN's Q4 (June–August) suggests CTSH's June quarter-end was also under pressure. This likely contributed to CTSH's sharp stock decline to its June 30 lows.

AI Demand & Larger AI Programs — 🟢 Positive Read-Through for CTSH

Sweet noted: "clients continue to invest in the foundations needed to scale AI" and "at least one out of every two advanced AI projects continuing to lead to a data project." She observed "exciting green shoots" as "clients with more advanced digital cores are starting to take on larger AI programs." On AI spend: "we're not seeing it be material to impact the spend on services today. And if anything, we think it's going to drive more to use services." AI demand is "building every quarter" with a "steady increase in the average size" of AI projects. ACN also noted it is "on track to more than double our bookings from our key emerging AI and data partners" vs. FY25.

CTSH Relevance: Strongly positive for CTSH's AI builder narrative. ACN's confirmation that AI is driving larger programs, more consulting work, and growing bookings from AI/data partners validates CTSH's large deal pipeline and its positioning around AI-led productivity (Vector 1) and AI readiness (Vector 2). The "green shoots" of larger AI programs is consistent with CTSH's own commentary about vector two gaining traction.

Deal Timing & Large Deal Slippage — 🟡 Mixed Read-Through for CTSH

ACN noted that "a couple of our large managed services opportunities moved into FY27 for company specific reasons" and that "longer decision making" was observed in EMEA. Sweet clarified these were company-specific rather than market-wide, but acknowledged the broader trend of macro uncertainty affecting deal timing.

CTSH Relevance: Moderately relevant. Large deal slippage at ACN is attributed to company-specific factors, limiting the direct read-through. However, the broader pattern of longer decision-making in EMEA and macro-driven caution is consistent with CTSH's own guidance commentary and could affect CTSH's bookings conversion in Q2.

Forward Guidance — 🔴 Negative Read-Through for CTSH Sector Sentiment

ACN cut full-year FY26 revenue guidance to 3–4% local currency growth (from prior range), or 4–5% excluding federal. Q4 FY26 guidance range of 1–5% local currency growth was described as having "more of the range in play" given macro uncertainty. Park noted the low end implies "ongoing deterioration," the middle implies "stabilization," and the high end implies "some improvement."

CTSH Relevance: The ACN guidance cut was the proximate trigger for CTSH's sharp decline in mid-to-late June. For the Q2 print, the key question is whether CTSH's own guidance (which was already cautious) proves more resilient than ACN's, given CTSH's higher exposure to BFSI (which ACN noted is benefiting from robust investment cycles) and its large deal ramp-up tailwind.

8B. IBM — Q2 2026 Earnings Call (July 22, 2026)

IBM's Q2 2026 (ended June 30, 2026) is the same calendar quarter as CTSH's Q2 2026. IBM's commentary on conditions during Q2 and its forward guidance for Q3 are directly relevant. Note: IBM's miss was driven primarily by CapEx-sensitive mainframe/software deals — a different demand dynamic than CTSH's services model — but the broader signals on enterprise IT spending and deal timing are meaningful.

Enterprise IT Spending Environment — 🟡 Mixed Read-Through for CTSH Q2

IBM CEO Arvind Krishna stated: "the technology spending environment remains dynamic." CFO Jim Kavanaugh elaborated: "In the final weeks of June, we saw a shift in client spending priorities. Many clients redirected spending towards servers, storage, and memory purchases to secure supply constrained infrastructure ahead of expected price increases." This shift caused "tens of large deals" to fail to close on expected timelines, "accounting for the majority of the shortfall." Critically, Kavanaugh distinguished: "subscription and consumption based software... were largely unaffected by the CapEx dynamics that impacted some of our [enterprise license agreement] transactions during the quarter."

CTSH Relevance: The CapEx-driven budget shift that hurt IBM is largely specific to IBM's mainframe/software stack and is not directly applicable to CTSH's services model. CTSH's revenue is predominantly OpEx-based (services, managed services, BPO), which IBM itself noted was "largely unaffected" by the CapEx dynamics. However, the broader signal of client budget re-prioritization and large deal slippage in the final weeks of June is a risk factor for CTSH's own Q2 bookings and deal closures.

Deal Timing — Deferred, Not Destroyed — 🟢 Positive Read-Through for CTSH Pipeline

Krishna expressed confidence that demand is "deferred and not destroyed," citing that "about a third of those [slipped deals] have already closed" in the first three weeks of Q3 (i.e., early July 2026). He stated: "the fact that a third have already closed in the first three weeks gives us an indication, not yet full evidence, but a good indication that this was deferral and not destruction."

CTSH Relevance: Positive read-through for CTSH's pipeline durability. If IBM's large deals are closing in early Q3, it suggests enterprise IT budgets are intact and deals are being deferred rather than cancelled — consistent with CTSH's own thesis that large deal ramps will be "meaningful second half drivers." This supports the case for H2 2026 revenue acceleration at CTSH.

AI Demand & Consulting Signings — 🟢 Positive Read-Through for CTSH

IBM's consulting signings grew 6% in Q2, "marking our second consecutive quarter of growth and reflecting continued client investment in business transformation initiatives." Consulting revenue grew 1%, "driven by demand for application modernization, data transformation, and cyber security services." On AI: "Generative AI represented about 50% of our signings in the quarter, and now makes up over 30% of our backlog, underscoring the demand for AI powered transformations that extend beyond technology modernization into core business operations as clients move from pilots to enterprise wide deployment." Krishna noted: "Clients remain in the early stages of AI adoption, making our combination of consulting expertise and technology a key differentiator."

CTSH Relevance: Strongly positive for CTSH's AI services and consulting pipeline. IBM's 6% consulting signings growth and the fact that GenAI now represents 50% of signings and 30% of backlog validates the enterprise AI adoption thesis that underpins CTSH's large deal momentum. The move "from pilots to enterprise wide deployment" is exactly the transition CTSH's AI builder strategy is designed to capture.

IBM Forward Guidance (Q3 2026) — 🟡 Mixed Read-Through for CTSH

IBM revised full-year revenue growth to 4–5% (from prior >5%), with the low end as the base case. For consulting, IBM expects "an acceleration in revenue growth to low to mid single digits for the year," driven by "the quality of our backlog and momentum in gen AI." Q3 constant currency revenue growth is expected to be "consistent with the full year." IBM also expects 100bps of operating pre-tax margin expansion for the full year.

CTSH Relevance: IBM's expectation of consulting acceleration in H2 2026, driven by GenAI backlog, is a positive read-through for CTSH's own H2 recovery thesis. The maintained margin expansion guidance despite revenue headwinds is also consistent with CTSH's Project Leap-driven margin story. The overall revenue guidance cut is a mild negative for sector sentiment but is largely IBM-specific given the mainframe cycle dynamics.

8C. DXC Technology — Investor Day (June 11, 2026)

DXC's June 11 Investor Day provided forward-looking commentary on the enterprise IT services market for FY2027 (DXC's fiscal year starting April 2026), which overlaps with CTSH's Q2 and H2 2026. DXC is a smaller, more distressed IT services peer, so read-throughs should be weighted accordingly — DXC-specific execution issues may not generalize to CTSH.

Discretionary Spend — 🔴 Negative Read-Through for CTSH Q2

DXC CFO Rob Del Bene explicitly stated: "we're assuming that the macro headwinds that we faced in smaller discretionary projects continues in fiscal 2027." This is a direct confirmation that the discretionary spend softness CTSH flagged at Q1 earnings is a market-wide phenomenon, not company-specific.

CTSH Relevance: Confirms the macro backdrop for CTSH's cautious Q2 guidance. The persistence of discretionary headwinds into DXC's FY27 (which starts April 2026) suggests CTSH's own H2 recovery assumptions may be optimistic if the macro environment does not improve.

AI Budgets & Deal Cycle Acceleration — 🟢 Positive Read-Through for CTSH

DXC CEO Raul Fernandez highlighted that AI is enabling dramatically faster deal cycles: "the cycle to impact, the cycle to revenue, the cycle to new customers, the cycle to new products has dramatically been cut." DXC noted new AI products can be "deployed within a quarter" and that its insurance AI pipeline reached "$100 million with over 100 different target customers" from a standing start in just a few months. DXC is targeting $1–1.5B in cost savings through internal AI adoption, with 75–80% of that target having "line of sight detailed plans."

CTSH Relevance: Positive for CTSH's AI monetization thesis. The rapid pipeline build and shortened deal cycles enabled by AI are consistent with CTSH's own commentary about AI-led productivity deals (Vector 1) converting quickly. DXC's internal AI cost savings target also validates the enterprise AI efficiency use case that CTSH is selling to clients.

AI as a Structural Reset — 🟢 Positive Read-Through for CTSH's AI Builder Positioning

DXC EVP Ramnath Venkataraman stated: "AI is that reset" for the business, putting DXC "at the front of the pack" in specific areas. DXC highlighted AI-led application services as the largest part of its business and is partnering with Anthropic to re-energize its core. DXC also noted the industry is "shifting from a labor arbitrage industry to an agent industry."

CTSH Relevance: Validates CTSH's broader thesis that AI is creating a structural reset in IT services, with the transition from labor arbitrage to agentic delivery creating new value pools. CTSH's more advanced AI builder positioning (vs. DXC's earlier-stage AI transformation) suggests CTSH is better positioned to capture this shift. The industry-wide acknowledgment of the labor-to-agent transition also supports CTSH's BPO and operations automation growth narrative.

Enterprise Application Bookings — 🟢 Positive Read-Through for CTSH

DXC CFO noted "strong bookings in enterprise application project sales in fiscal 26" that will "favorably impact fiscal 27 revenue performance." DXC's backlog improvements in both GIS and CES segments are expected to drive H2 revenue recovery.

CTSH Relevance: Consistent with CTSH's own large deal ramp-up thesis. Strong enterprise application bookings across the industry suggest the pipeline is healthy even if near-term discretionary spend is soft, supporting CTSH's expectation that large deal transitions from Q4 2025 and Q1 2026 will unlock in Q2–Q3 2026.

Peer Read-Through Summary

Sources: ACN Q3 FY2026 Earnings Call Transcript (June 18, 2026); IBM Q2 2026 Earnings Call Transcript (July 22, 2026); DXC Technology Investor Day Transcript (June 11, 2026).